Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Escitalopram Oxalate

FDA-approved product (tablet, oral), marketed as Escitalopram, Escitalopram Oxalate, Lexapro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Escitalopram Oxalate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Generalized anxiety disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Escitalopram Oxalate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Escitalopram Oxalate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

    NCT01870843 · start 2014-03

    Registered record
    Registry ID
    NCT01870843
    Conditions
    Depressive Disorder, Major
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-05
    Enrolment
    261

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Major
    InterventionEscitalopram
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers

    NCT02122939 · start 2013-09

    Registered record
    Registry ID
    NCT02122939
    Conditions
    Healthy
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEscitalopram
    PhasePhase 1
    Registry statusCompleted

  • Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

    NCT01838681 · start 2013-06

    Registered record
    Registry ID
    NCT01838681
    Conditions
    Major Depressive Disorder
    Interventions
    Placebo; Brexpiprazole; ADT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-06
    Enrolment
    1,986

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionPlacebo; Brexpiprazole; ADT
    PhasePhase 3
    Registry statusCompleted

  • Lexapro®'s Efficacy After Dose Escalation in Remission Study

    NCT01594866 · start 2012-05

    Registered record
    Registry ID
    NCT01594866
    Conditions
    Major Depressive Disorder
    Interventions
    escitalopram; escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-05
    Completion
    2016-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    Interventionescitalopram; escitalopram
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

    NCT01436162 · start 2011-10-19

    Registered record
    Registry ID
    NCT01436162
    Conditions
    Major Depressive Disorder
    Interventions
    Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-10-19
    Completion
    2013-12-10
    Enrolment
    1,105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAntidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo
    PhasePhase 3
    Registry statusCompleted

  • Escitalopram and Depression in Elderly Alzheimer's Patients

    NCT00488670 · start 2010-12

    Registered record
    Registry ID
    NCT00488670
    Conditions
    Depressive Disorder
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2011-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder
    InterventionEscitalopram
    PhasePhase 3
    Registry statusTerminated

  • Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

    NCT00958633 · start 2010-11

    Registered record
    Registry ID
    NCT00958633
    Conditions
    Bipolar I Disorder
    Interventions
    Escitalopram; Bupropion XL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-11
    Completion
    2020-05-20
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionEscitalopram; Bupropion XL
    PhasePhase 3
    Registry statusTerminated

  • Modafinil - Escitalopram Study for Cocaine Dependence

    NCT01601730 · start 2010-08

    Registered record
    Registry ID
    NCT01601730
    Conditions
    Cocaine Dependence; Cocaine Abuse; Cocaine Addiction; Substance Abuse
    Interventions
    Modafinil and Escitalopram; Placebo; Modafinil; Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-07
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence; Cocaine Abuse; Cocaine Addiction; Substance Abuse
    InterventionModafinil and Escitalopram; Placebo; Modafinil; Escitalopram
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

    NCT01111552 · start 2010-07-29

    Registered record
    Registry ID
    NCT01111552
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    Escitalopram; Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-07-29
    Completion
    2011-09-27
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    InterventionEscitalopram; Aripiprazole; Placebo
    PhasePhase 3
    Registry statusTerminated

  • The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF)

    NCT00989053 · start 2010-01

    Registered record
    Registry ID
    NCT00989053
    Conditions
    Depression; Anxiety; In Vitro Fertilization
    Interventions
    escitalopram; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-01
    Completion
    2012-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Anxiety; In Vitro Fertilization
    Interventionescitalopram; placebo
    PhaseNot applicable
    Registry statusUnknown

  • The Early Medication Change (EMC) Trial

    NCT00974155 · start 2009-09

    Registered record
    Registry ID
    NCT00974155
    Conditions
    Depression
    Interventions
    Escitalopram, venlafaxine, lithium; Escitalopram, venlafaxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2014-05
    Enrolment
    889

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionEscitalopram, venlafaxine, lithium; Escitalopram, venlafaxine
    PhasePhase 4
    Registry statusCompleted

  • Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

    NCT00905424 · start 2009-07-30

    Registered record
    Registry ID
    NCT00905424
    Conditions
    Major Depressive Disorder
    Interventions
    Antidepressant + SPD489 (lisdexamfetamine dimesylate); Antidepressant + placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07-30
    Completion
    2010-08-04
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAntidepressant + SPD489 (lisdexamfetamine dimesylate); Antidepressant + placebo
    PhasePhase 2
    Registry statusCompleted

  • Escitalopram in Patients With Generalized Anxiety Disorder

    NCT00902564 · start 2009-03

    Registered record
    Registry ID
    NCT00902564
    Conditions
    Generalized Anxiety Disorder
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionEscitalopram
    PhasePhase 4
    Registry statusCompleted

  • Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

    NCT01541475 · start 2009-03

    Registered record
    Registry ID
    NCT01541475
    Conditions
    Major Depressive Disorder
    Interventions
    Bupropion, Escitalopram; Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2011-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionBupropion, Escitalopram; Escitalopram
    PhasePhase 4
    Registry statusCompleted

  • Escitalopram Treatment of Night Eating Syndrome

    NCT00636649 · start 2008-10

    Registered record
    Registry ID
    NCT00636649
    Conditions
    Night Eating Syndrome
    Interventions
    Escitalopram; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNight Eating Syndrome
    InterventionEscitalopram; Placebo
    PhaseNot applicable
    Registry statusCompleted